AC Immune SA

ACIU · NASDAQ

AC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commitment before the runway becomes the thesis.

Follow Add to Watchlist Ask Question

NASDAQ ACIU Coverage Bootstrap Biotechnology Neurodegeneration Alzheimer's Disease

Latest ReportMay 13, 2026AC Immune: five neurodegeneration shots before the 2027 cash clock ringsView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.